<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 05 Feb 2021 16:28:18 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>经典永流传，单克隆抗体简史！</title><link>https://mp.weixin.qq.com/s/a-I9lfPEXUOnhKLLa3_KeQ</link><description></description><content:encoded><![CDATA[经典永流传，单克隆抗体简史！]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:01:38 +0800</pubDate></item><item><title>新江湖｜锐得麦医药加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/_2zn3Y6jaNHXYBVecDyqyQ</link><description></description><content:encoded><![CDATA[新江湖｜锐得麦医药加入BiG会员机构！]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:01:38 +0800</pubDate></item><item><title>Chugai制药神来之笔：肿瘤微环境抗体定向技术</title><link>https://mp.weixin.qq.com/s/UmlOGxZwuGBeXxnX9Ej7pA</link><description></description><content:encoded><![CDATA[Chugai制药神来之笔：肿瘤微环境抗体定向技术]]></content:encoded><pubDate>Wed, 03 Feb 2021 17:38:38 +0800</pubDate></item><item><title>新江湖｜戴晓兵、李成涛、李洁、何立峰加入BiG！</title><link>https://mp.weixin.qq.com/s/z7PpFRxSxWbm9AbkpdpWtw</link><description></description><content:encoded><![CDATA[新江湖｜戴晓兵、李成涛、李洁、何立峰加入BiG！]]></content:encoded><pubDate>Wed, 03 Feb 2021 17:38:38 +0800</pubDate></item><item><title>二十载IL-36：炎症与肿瘤</title><link>https://mp.weixin.qq.com/s/5rUSOsHXY7FmCxnzLyrAFw</link><description></description><content:encoded><![CDATA[二十载IL-36：炎症与肿瘤]]></content:encoded><pubDate>Wed, 03 Feb 2021 17:38:38 +0800</pubDate></item><item><title>AML治疗新策略，CD33双抗！</title><link>https://mp.weixin.qq.com/s/y4j0jgtuVILD5d6678cKjA</link><description></description><content:encoded><![CDATA[AML治疗新策略，CD33双抗！]]></content:encoded><pubDate>Mon, 01 Feb 2021 17:22:53 +0800</pubDate></item><item><title>新江湖｜益莱生物加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/ea3sqP9h4bf6PVyWQUSJbA</link><description></description><content:encoded><![CDATA[新江湖｜益莱生物加入BiG会员机构！]]></content:encoded><pubDate>Mon, 01 Feb 2021 17:22:53 +0800</pubDate></item><item><title>王晓东｜从NIBS走出的维泰瑞隆，做药的逻辑是什么？</title><link>https://mp.weixin.qq.com/s/v6A4IXS_2LCUwZf2J-rsag</link><description></description><content:encoded><![CDATA[王晓东｜从NIBS走出的维泰瑞隆，做药的逻辑是什么？]]></content:encoded><pubDate>Thu, 28 Jan 2021 18:02:49 +0800</pubDate></item><item><title>多抗潮头，创药蓝海｜第七届BiG年会来了！</title><link>https://mp.weixin.qq.com/s/qgqCame67NjttxHhUkbJzw</link><description></description><content:encoded><![CDATA[多抗潮头，创药蓝海｜第七届BiG年会来了！]]></content:encoded><pubDate>Thu, 28 Jan 2021 17:56:01 +0800</pubDate></item><item><title>进击吧，细胞因子！IL-2和IL-15的单药及Combo</title><link>https://mp.weixin.qq.com/s/sffBLdxE1wbndXp9BQqTig</link><description></description><content:encoded><![CDATA[进击吧，细胞因子！IL-2和IL-15的单药及Combo]]></content:encoded><pubDate>Wed, 27 Jan 2021 17:01:53 +0800</pubDate></item><item><title>新江湖｜ 春天医药加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/1sJIoQZC3UosU99bLFDS0Q</link><description></description><content:encoded><![CDATA[新江湖｜ 春天医药加入BiG会员机构！]]></content:encoded><pubDate>Wed, 27 Jan 2021 17:01:53 +0800</pubDate></item><item><title>Nature Cancer｜新型ADC：Bolt Bio公司ISACs</title><link>https://mp.weixin.qq.com/s/GPjMctX-31whm08tADGvWw</link><description></description><content:encoded><![CDATA[Nature Cancer｜新型ADC：Bolt Bio公司ISACs]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:01:35 +0800</pubDate></item><item><title>荐 | 保护药品研发成果，这2项专利制度你必须知道！</title><link>https://mp.weixin.qq.com/s/lxTPJxhmi2pTycA7vFqS3Q</link><description></description><content:encoded><![CDATA[荐 | 保护药品研发成果，这2项专利制度你必须知道！]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:01:35 +0800</pubDate></item><item><title>盘点｜肿瘤干细胞药物开发的四条通路及主要靶点！</title><link>https://mp.weixin.qq.com/s/e_cvInoUSPsnN14ZDnskvw</link><description></description><content:encoded><![CDATA[盘点｜肿瘤干细胞药物开发的四条通路及主要靶点！]]></content:encoded><pubDate>Fri, 22 Jan 2021 15:48:53 +0800</pubDate></item><item><title>新江湖｜徐琦、刘佳凝、朱枫、郎帼娜、张妍加入BiG！</title><link>https://mp.weixin.qq.com/s/409dsez7olZOYA6cYjrWxQ</link><description></description><content:encoded><![CDATA[新江湖｜徐琦、刘佳凝、朱枫、郎帼娜、张妍加入BiG！]]></content:encoded><pubDate>Fri, 22 Jan 2021 15:48:53 +0800</pubDate></item><item><title>又一重磅Deal, 科望医药1.17亿美元引入VEGF/DLL4双抗！</title><link>https://mp.weixin.qq.com/s/8oFUIgWiSOFLQfIT4OQ-Jg</link><description></description><content:encoded><![CDATA[又一重磅Deal, 科望医药1.17亿美元引入VEGF/DLL4双抗！]]></content:encoded><pubDate>Thu, 21 Jan 2021 13:00:35 +0800</pubDate></item><item><title>五位大咖谈IO｜单抗/ADC赛道，新靶点如何困境突围？</title><link>https://mp.weixin.qq.com/s/g1qSsbCfB4nXK9KEUGdRMA</link><description></description><content:encoded><![CDATA[五位大咖谈IO｜单抗/ADC赛道，新靶点如何困境突围？]]></content:encoded><pubDate>Tue, 19 Jan 2021 17:00:05 +0800</pubDate></item><item><title>新江湖｜自贸壹号加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/nT6b1qb23k0zea_VOA6jBg</link><description></description><content:encoded><![CDATA[新江湖｜自贸壹号加入BiG会员机构！]]></content:encoded><pubDate>Tue, 19 Jan 2021 17:00:05 +0800</pubDate></item></channel></rss>